Neumora Therapeutics (NMRA) Profit After Tax (2022 - 2026)

Neumora Therapeutics' Profit After Tax history runs 5 years deep, the most recent figure standing at -$53.5 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 21.45% year-over-year to -$53.5 million; the TTM figure through Mar 2026 stood at -$222.4 million (up 13.79% YoY), while the FY2025 annual figure was -$237.0 million, up 2.73% from the prior year.
• Profit After Tax for Q1 2026 stood at -$53.5 million, up from -$59.5 million in the prior quarter.
• The five-year high for Profit After Tax was -$28.9 million in Q4 2022, with the low at -$109.2 million in Q4 2023.
• The 5-year median for Profit After Tax is -$53.7 million (2024), against an average of -$55.3 million.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax slumped 277.57% in 2023, then jumped 46.26% in 2024.
• Neumora Therapeutics' Profit After Tax stood at -$28.9 million in 2022, then plunged by 277.57% to -$109.2 million in 2023, then surged by 46.26% to -$58.7 million in 2024, then decreased by 1.33% to -$59.5 million in 2025, then rose by 10.09% to -$53.5 million in 2026.
• Business Quant data shows NMRA's Profit After Tax at -$53.5 million in Q1 2026, -$59.5 million in Q4 2025, and -$56.8 million in Q3 2025.